Cardiol Therapeutics (TSE:CRDL) Trading 1.3% Higher – Still a Buy?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price shot up 1.3% during trading on Thursday . The company traded as high as C$1.56 and last traded at C$1.51. Approximately 48,612 shares were traded during trading, a decline of 50% from the average session volume of 97,890 shares. The stock had previously closed at C$1.49.

Cardiol Therapeutics Stock Up 1.3%

The company has a market cap of C$174.06 million, a PE ratio of -3.87 and a beta of 0.37. The firm has a 50-day simple moving average of C$1.74 and a two-hundred day simple moving average of C$1.56. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.39 and a quick ratio of 6.84.

Cardiol Therapeutics (TSE:CRDL) last issued its quarterly earnings data on Monday, May 11th. The company reported C($0.10) earnings per share (EPS) for the quarter. Research analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.